J. Machiels

V. Grégoire, J. Machiels, M. Hamoir, 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Cancer risk in immune-mediated inflammatory diseases (IMID)

E. Louis, J. Renauld, J. Machiels, 2013, Molecular Cancer.

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

J. Machiels, F. Piette, K. Odunsi, 2017, BMJ Open.

Celyad's novel CAR T-cell therapy for solid malignancies.

J. Machiels, J. Canon, K. Odunsi, 2018, Current Research in Translational Medicine.

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results

J. Machiels, A. Awada, G. Jerusalem, 2020, Acta clinica Belgica.

LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen.

J. Machiels, M. Berlière, C. Galant, 2004, European journal of cancer.

Unreliability of carcinoembryonic antigen (CEA) reverse transcriptase-polymerase chain reaction (RT-PCR) in detecting contaminating breast cancer cells in peripheral blood stem cells due to induction of CEA by growth factors

J. Machiels, M. Salmon, V. D’Hondt, 1999, Bone Marrow Transplantation.

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors

J. Machiels, P. Maison-Blanche, S. Dakhil, 2014, Cancer Chemotherapy and Pharmacology.

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

J. Machiels, J. Tabernero, R. Kurzrock, 2014, Clinical Cancer Research.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

A. Ravaud, S. Culine, J. Machiels, 2017, European urology.

Venovenous ECMO in life-threatening radiocontrast mediated-ARDS

J. Machiels, P. Bulpa, A. Dive, 1999, Intensive Care Medicine.

Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?

C. Sempoux, J. Machiels, J. Canon, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.

C. Sempoux, J. Machiels, V. Remouchamps, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases.

C. Sempoux, J. Machiels, Y. Humblet, 2010, Surgery.

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

T. Brümmendorf, J. Machiels, J. Delord, 2013, Investigational New Drugs.

Cancer and renal insufficiency results of the BIRMA study

J. Machiels, H. Wildiers, J. Canon, 2010, British Journal of Cancer.

The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease.

V. Grégoire, J. Machiels, B. Weynand, 2012, Oral oncology.

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

J. Machiels, R. Mathijssen, M. D. de Jonge, 2016, Cancer Chemotherapy and Pharmacology.

Advances in the management of squamous cell carcinoma of the head and neck

V. Grégoire, J. Machiels, M. Hamoir, 2014, F1000prime reports.

Reprint of "Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

V. Grégoire, J. Machiels, C. Grau, 2020, Oral oncology.

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.

V. Grégoire, J. Machiels, K. Harrington, 2020, Future oncology.

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

V. Grégoire, J. Machiels, C. Grau, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.

J. Machiels, T. Gauler, B. Melichar, 2019, Oral oncology.

Systemic Treatments: Chemotherapy and Targeted Therapies

J. Machiels, S. Schmitz, 2017 .

Safety of drug treatments for head and neck cancer

J. Machiels, R. Galot, 2016, Expert opinion on drug safety.

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours

J. Machiels, O. Feron, R. Boidot, 2013, British Journal of Cancer.

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

J. Machiels, K. Korski, G. Meneses‐Lorente, 2022, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

J. Machiels, R. Salazar, B. Champion, 2019, Journal of Immunotherapy for Cancer.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

J. Machiels, K. Miller, P. Karakiewicz, 2012, European journal of cancer.

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.

J. Machiels, M. Campone, X. Pivot, 2011, European journal of cancer.

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

J. Machiels, E. Tartour, W. Fridman, 2011, Cancer Immunology, Immunotherapy.

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

J. Machiels, B. Tombal, B. Filleul, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.

J. Bourhis, J. Machiels, C. Sire, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

The promise of immunostimulatory antibodies in head and neck cancer.

J. Machiels, P. Coulie, 2016, The Lancet. Oncology.

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

J. Machiels, A. Awada, V. Cocquyt, 2010, BMC Cancer.

Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

J. Machiels, C. Belka, Y. Guo, 2021, ESMO open.

Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck

D. Vertommen, J. Machiels, P. Roger, 2020, Molecular Cancer Therapeutics.

Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response

E. Jaffee, J. Machiels, L. Emens, 2005, The Journal of experimental medicine.

Amplification of epidermal growth factor receptor gene in renal cell carcinoma.

A. Ravaud, J. Machiels, C. Sternberg, 2010, European journal of cancer.

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.

K. Bensalah, J. Patard, A. Ravaud, 2015, Urologic oncology.

Metabolic Imaging Using Hyperpolarized Pyruvate–Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts

J. Machiels, O. Feron, Patrice D Cani, 2019, Clinical Cancer Research.

Docetaxel rechallenge after an initial good response in patients with metastatic castration‐resistant prostate cancer

J. Machiels, G. Kramer, S. Oudard, 2015, BJU international.

Retrovirus-mediated gene transfer of the human multidrug resistance-associated protein into hematopoietic cells protects mice from chemotherapy-induced leukopenia.

J. Machiels, A. Feyens, V. D’Hondt, 1999, Human gene therapy.

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy

J. Machiels, G. Berchem, A. van Maanen, 2015, The oncologist.

Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.

J. Machiels, N. Michoux, B. Weynand, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction Chemotherapy: Does It Have a Place in Oral Cavity Cancer?

J. Machiels, 2018 .

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

C. R. Leemans, J. Machiels, P. Bruzzi, 2019, Journal of Immunotherapy for Cancer.

Is there a Role for Neoadjuvant Targeted Therapy and Immunotherapy?

J. Machiels, S. Beyaert, 2021, Critical Issues in Head and Neck Oncology.

A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel

J. Machiels, P. Maison-Blanche, D. Strumberg, 2013, Journal of cardiovascular pharmacology.

Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.

J. Machiels, L. De Cecco, M. Serafini, 2022, Oral oncology.

Acute cardiac failure after sunitinib.

J. Machiels, L. Jacquet, N. Blétard, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib

D. Lambrechts, J. Machiels, E. Lerut, 2019, Acta clinica Belgica.

Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy

J. Machiels, B. Tombal, E. Danse, 2013, Urologia Internationalis.

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

A. Ravaud, J. Machiels, G. Deplanque, 2015, European urology.

Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium

J. Machiels, N. Lumen, P. Debruyne, 2014, Acta clinica Belgica.

Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.

J. Machiels, J. Bendell, B. O'Neil, 2013 .

Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel

J. Machiels, M. Berlière, F. Dalenc, 2008, BMC Cancer.

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a prospective cohort study

J. Machiels, E. Seront, M. Gizzi, 2020 .

Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)

J. Machiels, C. Sternberg, J. Bellmunt, 2013, Oncology.

Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group

J. Machiels, P. Bossi, C. Simon, 2022, Frontiers in Oncology.

HER2 and HER3 in HPV+ and HPV− HNSCC—Letter

J. Machiels, S. Schmitz, R. Galot, 2016, Clinical Cancer Research.

Reply to Letter to the Editor 'Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?', by M. G. Fakih (Ann Oncol 2006; 17: 1029).

J. Machiels, P. Scalliet, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

J. Machiels, M. Berlière, F. Dalenc, 2011 .

Retroviral-mediated gene transfer of human multidrug resistance associated murine hematopoietic cells

J. Machiels, A. Feyens, V. D’Hondt, 1998 .

Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

J. Machiels, Y. Bang, A. Italiano, 2021, Clinical Cancer Research.

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

C. Porta, A. Ravaud, R. Figlin, 2016, Clinical genitourinary cancer.

Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature

J. Machiels, G. Kornek, A. Robert, 2007, European Archives of Oto-Rhino-Laryngology.

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.

J. Machiels, E. Van Cutsem, P. Pauwels, 2021, Critical reviews in oncology/hematology.

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz, S. Culine, J. Hainsworth, 2022, The Lancet. Oncology.

Cytokine gene-modified cell-based cancer vaccines.

E. Jaffee, J. Machiels, L. Emens, 2002, Methods in molecular medicine.

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer

N. Agarwal, J. Machiels, K. Wisinski, 2016, The oncologist.

Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up

J. Machiels, A. Trama, L. Smeele, 2022, ESMO open.

Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)

R. Figlin, J. Machiels, I. Davis, 2007 .

Combined radiotherapy and chemotherapy

V. Grégoire, J. Machiels, M. Baumann, 2009, Basic Clinical Radiobiology.

Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

C. Sempoux, J. Machiels, K. Haustermans, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liver insufficiency due to breast cancer metastases Fast biological response with capecitabine

J. Machiels, J. Baurain, S. Henry, 2004, Acta oncologica.

Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study

J. Machiels, G. Deplanque, S. Oudard, 2007 .

Peritoneal carcinomatosis and prostatic cancer: a rare manifestation of the disease with an impact on management.

J. Machiels, B. Tombal, L. Annet, 2013, JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie.

International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic

Hung-Ming Wang, V. Grégoire, J. Machiels, 2022, The Lancet Oncology.

NEW DRUGS IN MEDICAL ONCOLOGY: NEW DIFFICULTIES TO DISTINGUISH DRUG-INDUCED SIDE EFFECTS FROM CANCER COMPLICATIONS: A CASE-REPORT

J. Machiels, Y. Humblet, E. Seront, 2011, Acta clinica Belgica.

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

J. Machiels, M. Berlière, Y. Humblet, 2003, Gynecologic oncology.

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

J. Machiels, T. Seiwert, A. Psyrri, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib

N. Rioux-Leclercq, D. Lambrechts, J. Zucman‐Rossi, 2020 .

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

J. Machiels, S. Srinivas, J. Picus, 2012, Clinical Cancer Research.

Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma

J. Machiels, K. Harrington, M. Ahn, 2018, Clinical Trials.

Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma.

J. Machiels, S. Bhide, K. Harrington, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of Life With Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.

J. Machiels, K. Harrington, M. Ahn, 2020, Journal of the National Cancer Institute.

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

E. Jaffee, J. Machiels, L. Emens, 2001, Cancer research.

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

J. Machiels, F. D. De Braud, Z. Tsuchihashi, 2022, Journal of Clinical Oncology.

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

K. Pienta, J. Machiels, C. Takimoto, 2013, Investigational New Drugs.

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

J. Machiels, K. Korski, G. Meneses‐Lorente, 2020, Journal for ImmunoTherapy of Cancer.

Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.

J. Machiels, C. Corbet, S. Schmitz, 2022, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

R. Plummer, J. Machiels, D. Hong, 2019, The Lancet. Oncology.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival

J. Machiels, J. Galon, Y. Humblet, 2018, Journal of the National Cancer Institute.

Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck

J. Machiels, S. Schmitz, 2016, Current Treatment Options in Oncology.

Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.

T. Zander, J. Machiels, J. Schellens, 2019, JCO precision oncology.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Vaccine-Based Immunotherapy for Head and Neck Cancers

J. Machiels, S. Schmitz, S. Beyaert, 2021, Cancers.

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

B. Mellado, J. Machiels, L. Dirix, 2017, European journal of cancer.

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck

J. Machiels, T. Gauler, S. Braun, 2015, Cancer Chemotherapy and Pharmacology.

Metastatic Castrate-resistant Prostate Cancer: When and How to Treat?

J. Machiels, Donatienne L. Taylor, 2014 .

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

J. Machiels, J. Canon, B. Sautois, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck

J. Machiels, Mariama El Baroudi, S. Schmitz, 2017, Cancer biology & therapy.

Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications

J. Machiels, S. Schmitz, 2010, Expert review of anticancer therapy.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Ulrich Keilholz, Thomas Gauler, J. Machiels, 2015, The Lancet. Oncology.

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial.

J. Machiels, I. Tinhofer, J. Canon, 2021, European journal of cancer.

Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial.

J. Machiels, K. Harrington, M. Ahn, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

J. Machiels, D. Rischin, R. Swaby, 2022, Annals of Oncology.

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck

J. Machiels, A. van Maanen, E. Seront, 2019, Front. Oncol..

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

J. Machiels, S. Hansen, S. Oudard, 2010, The Lancet.

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

C. Sempoux, J. Machiels, K. Haustermans, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.

J. Machiels, S. Rottey, J. Vermorken, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?

Laurence Collette, Jean-Pascal Machiels, François Jamar, 2012, European urology.

Multidisciplinary Management of Hypopharyngeal Carcinoma

V. Grégoire, J. Machiels, M. Hamoir, 2011 .

Antivascular Therapy for Epithelial Ovarian Cancer

J. Machiels, F. Duhoux, 2009, Journal of oncology.

Fibroblast Growth Factor Receptor‐2 Polymorphism rs2981582 is Correlated With Progression‐free Survival and Overall Survival in Patients With Metastatic Clear‐cell Renal Cell Carcinoma Treated With Sunitinib

D. Lambrechts, J. Zucman‐Rossi, J. Machiels, 2019, Clinical genitourinary cancer.

Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear‐Cell Renal‐Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors

J. Patard, D. Lambrechts, J. Zucman‐Rossi, 2018, Clinical genitourinary cancer.

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.

Frank Pétavy, Jean-Pascal Machiels, Patrick Schöffski, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

R. Greil, J. Machiels, T. Dorff, 2020 .

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).

R. Greil, J. Machiels, T. Dorff, 2020 .

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

J. Machiels, F. D. De Braud, M. Tiseo, 2020, Cancers.

Phase IB Dose-Escalation Study of BEZ235 or BKM120 in Combination with Paclitaxel (PTX) in Patients With Advanced Solid Tumors

J. Machiels, L. Dirix, L. Paz-Ares, 2012 .

Cancers of the Urinary System

J. Machiels, A. Parsyan, E. Seront, 2014 .

Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer.

B. De Moor, O. Gevaert, A. Debucquoy, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

G. Salles, J. Machiels, D. Cunningham, 2019, Molecular Cancer Therapeutics.

Do Intraoperative Analgesics Influence Breast Cancer Recurrence After Mastectomy? A Retrospective Analysis

J. Machiels, P. Forget, M. Berlière, 2010, Anesthesia and analgesia.

Molecular biology and targeted therapies for urothelial carcinoma.

J. Machiels, E. Seront, 2015, Cancer treatment reviews.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

A. Jimeno, J. Machiels, T. Seiwert, 2016, Cancer.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

A. Ravaud, J. Machiels, B. Esterni, 2013, The Lancet. Oncology.

Integration of Epidermal Growth Factor Receptor Inhibitors with Preoperative Chemoradiation

Karin Haustermans, Jean-Pascal Machiels, A. Debucquoy, 2010, Clinical Cancer Research.

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.

J. Machiels, J. Bogaerts, I. Tinhofer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact

J. Machiels, C. van Marcke, N. Limaye, 2021, Cancers.

Unusual Metastatic Features in a Patient with Concomitant Malignant Orbital Melanoma and Prostate Carcinoma

J. Machiels, J. Baurain, P. Moulin, 2004, Journal of Neuro-Oncology.

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

J. Machiels, F. Penault-Llorca, B. Asselain, 2012, The oncologist.

A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer.

J. Machiels, J. Canon, S. Oudard, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of selective neck dissection in the primary management of head and neck squamous cell carcinoma

V. Grégoire, J. Machiels, B. Weynand, 2009, European Archives of Oto-Rhino-Laryngology.

Metastatic signet-ring cell carcinoma of unknown primary origin

J. Machiels, J. Goeminne, C. Grégoire, 2014, Acta clinica Belgica.

Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

J. Machiels, M. Lacroix-Triki, M. Campone, 2014, Breast Cancer Research.

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck

J. Machiels, N. Michoux, R. Lhommel, 2015, Radiology and oncology.

Blockage of EGFR Pathway for Anticancer Therapy in Squamous Cell Carcinoma of the Head and Neck

J. Machiels, S. Schmitz, 2017 .

Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions.

J. Machiels, M. Hamoir, G. Wolf, 2014, Cancer treatment reviews.

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

J. Machiels, N. Michoux, S. Faivre, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.

A. Ashworth, J. Blay, W. Bodmer, 2014, Cancer research.

Which Factors Predict Overall Survival in Patients With Metastatic Castration‐Resistant Prostate Cancer Treated With Abiraterone Acetate Post‐Docetaxel?

J. Machiels, N. Lumen, P. Werbrouck, 2017, Clinical genitourinary cancer.

Impact of Cabazitaxel (CBZ) + Prednisone (P; CBZP) on Overall Survival (OS) At 2 Yrs and in Patients (PTS) with Aggressive Disease: Post-Hoc Analyses of Tropic Trial

J. Machiels, J. Bono, S. Oudard, 2012 .

Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck

J. Machiels, Gabrielle van Caloen, 2019, Current opinion in oncology.

Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study.

J. Machiels, Y. Humblet, M. Beauduin, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors

J. Machiels, E. Van Cutsem, G. Abou-Alfa, 2023, Targeted Oncology.

New advances in targeted therapies for squamous cell carcinoma of the head and neck

J. Machiels, S. Schmitz, 2011, Anti-cancer drugs.

LBA45_PRPembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

J. Machiels, K. Harrington, M. Ahn, 2017 .

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

A. Ravaud, S. Culine, J. Machiels, 2015, European journal of cancer.

A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

J. Machiels, L. Dirix, J. Canon, 2019, Annals of Oncology.

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.

J. Machiels, S. Lisby, Igor Lifirenko, 2011, The Lancet. Oncology.

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J. Machiels, L. Smeele, A. Trama, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients.

A. Debucquoy, J. Machiels, K. Haustermans, 2018, Cancer cell.

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

J. Machiels, T. Meyer, S. Topalian, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

W. Mason, J. Machiels, B. Melichar, 2022, ESMO open.

A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma

J. Machiels, D. Richel, M. Grimm, 2009, Cancer.

One‐step TNM staging of high‐risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all‐in‐one” imaging approach?

Laurence Collette, François Jamar, Nicolas Michoux, 2014, The Prostate.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

J. Machiels, T. Delozier, F. Penault-Llorca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment.

J. Machiels, R. de Bree, M. Hamoir, 2012, Oral oncology.

Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy

J. Machiels, D. A. D. de Andrade, 2012, Current opinion in oncology.

Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck

Jean-Pascal Machiels, J. Machiels, S. Schmitz, 2011, Expert review of anticancer therapy.

A phase I study of volasertib combined with afatinib, in advanced solid tumors

J. Machiels, N. Strelkowa, M. Peeters, 2015, Cancer Chemotherapy and Pharmacology.

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.

J. Machiels, A. Awada, J. Brayer, 2023, The Lancet. Haematology.

Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice1

E. Jaffee, J. Machiels, J. Slansky, 2003, The Journal of Immunology.

A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract. Interim analysis. : Abstract #4615

J. Machiels, D. Richel, M. Grimm, 2004 .

658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040

J. Machiels, K. Harrington, R. Mehra, 2022, Annals of Oncology.

Primary combined squamous and small cell carcinoma of the larynx: report of two cases and discussion of treatment modalities

V. Grégoire, J. Machiels, B. Weynand, 2006, European Archives of Oto-Rhino-Laryngology and Head & Neck.

Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

Hung-Ming Wang, V. Grégoire, J. Machiels, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Distant metastases from head and neck squamous cell carcinoma. Part II. Diagnosis.

C. R. Leemans, J. Machiels, R. de Bree, 2012, Oral oncology.

HER-2 / neu-Transgenic Mice Mammary Tumors from Class I Epitope Presented by Spontaneous Immunodominant Rat HER-2 / neu MHC Identification and Characterization of

J. Machiels, J. Slansky, Yi Cheng Chen, 2003 .

Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.

J. Machiels, R. Helaers, M. Vikkula, 2020, Oral oncology.

Epithelial–myoepithelial carcinoma of the submandibular gland with symptomatic lung metastases treated with chemotherapy

V. Grégoire, J. Machiels, B. Weynand, 2006, European Archives of Oto-Rhino-Laryngology and Head & Neck.

Late intensification chemotherapy with autologous bone marrow infusion in small cell lung cancer: preliminary results of a randomized trial

J. Machiels, Y. Humblet, L. Delaunois, 1984 .

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

J. Machiels, M. Ahn, T. Seiwert, 2016 .

2′-deoxy-2′-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck

V. Grégoire, J. Machiels, N. Michoux, 2018, Oncotarget.

Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.

J. Machiels, S. Schmitz, 2015, Hematology/oncology clinics of North America.

HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.

J. Machiels, M. Van den Eynde, A. De Cuyper, 2020, Clinical colorectal cancer.

Integrating Microarray and Proteomics Data to Predict the Response of Cetuximab in Patients with Rectal Cancer

B. Moor, T. D. Bie, O. Gevaert, 2007, Pacific Symposium on Biocomputing.

Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer

V. Grégoire, M. Groenvold, M. Sprangers, 2020, Head & neck.

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

J. Machiels, L. Licitra, R. Haddad, 2014, BMC Cancer.

A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract

J. Machiels, D. Richel, M. Groot, 2005 .

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

J. Machiels, T. Gauler, N. Gibson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Seeding of the percutaneous endoscopic gastrostomy site from head and neck carcinoma: Case report and review of the literature

J. Machiels, M. Hamoir, S. Schmitz, 2013, Head & neck.

May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?

J. Machiels, E. Seront, P. Bossi, 2019, Oral oncology.

Oncological care organisation during COVID-19 outbreak

J. Machiels, H. Rugo, H. Wildiers, 2020, ESMO Open.

An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.

J. Machiels, T. Meyer, S. Topalian, 2017 .

Evaluation of DCE-MRI postprocessing techniques to assess metastatic bone marrow in patients with prostate cancer.

Jean-Pascal Machiels, Frank Peeters, Frédéric Lecouvet, 2012, Clinical imaging.

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.

J. Machiels, N. Lumen, P. Werbrouck, 2016, Urologic oncology.

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

P. Jänne, P. Ascierto, P. V. Van Schil, 2020, Annals of Oncology.

Chemotherapy: friend or foe to cancer vaccines?

E. Jaffee, J. Machiels, L. Emens, 2001, Current opinion in molecular therapeutics.

Squamous Cell Carcinoma of the Head and Neck

J. Machiels, E. Seront, S. Schmitz, 2019, International Manual of Oncology Practice.

260 A phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma: the RadiOxCape study

C. Sempoux, J. Machiels, P. Scalliet, 2003 .

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

A. Ravaud, J. Machiels, B. Esterni, 2014, European journal of cancer.

A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC).

J. Machiels, J. Picus, G. Gravis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.

J. Machiels, K. Harrington, R. Swaby, 2015 .

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Treatment landscape of metastatic prostate cancer: the role of radium-223

J. Machiels, A. Dermine, 2017, Acta clinica Belgica.

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Y. Drew, J. Machiels, Melissa L. Johnson, 2019, Clinical Cancer Research.

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

J. Machiels, M. Hamoir, L. Knoops, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer

R. Semrau, A. Debucquoy, C. Sempoux, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer

R. Semrau, A. Debucquoy, C. Sempoux, 2011 .

What is the best way to predict disease-free survival after preoperative radiochemotherapy for rectal cancer patients: tumor regression grading, nodal status, or circumferential resection margin invasion?

C. Sempoux, J. Machiels, S. Aydın, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unmet Needs and Perspectives in Oral Cancer Prevention

P. Martinez, V. Grégoire, J. Machiels, 2022, Cancers.

Multicenter Randomized Phase 2 Trial of Gemcitabine – Platinum with or without Trastuzumab (T) in Advanced / Metastatic Urothelial Carcinoma (A/MUC) with HER2 Overexpression

A. Ravaud, S. Culine, J. Machiels, 2012 .

Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)

J. Machiels, L. De Cecco, S. Canevari, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck

D. Vertommen, J. Machiels, P. Roger, 2021, Cancers.

Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti‐androgen therapy—A case report

J. Machiels, M. Hamoir, S. Schmitz, 2020, Clinical case reports.

Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial

J. Machiels, P. Forget, P. Coulie, 2019, PloS one.

Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery.

J. Machiels, P. Forget, P. Coulie, 2014, British journal of anaesthesia.

A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer

J. Machiels, K. Zaman, Y. Humblet, 2011, Breast Cancer Research and Treatment.

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

J. Machiels, A. van Maanen, E. Seront, 2021, BMC cancer.

Whole Body MRI in the Detection of Lymph Node Metastases in Patients with Testicular Germ Cell Cancer

J. Machiels, N. Michoux, B. Tombal, 2022, Life.

Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer.

D. Amadori, J. Machiels, F. Cardoso, 2009 .

Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors

J. Machiels, R. Kurzrock, L. Dirix, 2012 .

La double affiliation du psycho-oncologue : entre cancérologie et psychiatrie de liaison = The psycho-oncologist double affiliation: Between cancerology and liaison consultation psychiatry

J. Machiels, E. Zech, P. Timary, 2012 .

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses

G. Scagliotti, J. Machiels, T. Dorff, 2022, The Oncologist.

Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors

J. Machiels, G. Curigliano, A. Santoro, 2019 .

Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC).

D. Lacombe, J. Machiels, Yan Liu, 2017, European journal of cancer.

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.

D. Amadori, J. Machiels, F. Cardoso, 2012, Breast.

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

R. Figlin, J. Machiels, R. Epstein, 2010 .

Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy

J. Machiels, S. Schmitz, 2011, Current opinion in oncology.

A prospective randomized study of two alternating, non cross-resistant chemotherapies for advanced Hodgkin's disease.

J. Machiels, P. Martiat, C. Doyen, 1992, Acta clinica Belgica.

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial

J. Machiels, T. Gauler, F. Caponigro, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results.

J. Machiels, M. Campone, X. Pivot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours.

J. Machiels, A. Awada, P. Schöffski, 2023, European journal of cancer.

LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy.

J. Machiels, E. Cohen, R. Haddad, 2012 .

1204 ORAL A Phase lb Open-label Study to Assess Continuous Oral Treatment With Afatinib (BIBW 2992) in Combination With Two Chemotherapy Regimens – Cisplatin Plus Paclitaxel, and Cisplatin Plus 5-fluorouracil in Patients, With Advanced Solid Tumours

J. Machiels, S. Rottey, J. Vermorken, 2011 .

TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES

P. Neven, J. Machiels, J. Canon, 2009, Acta clinica Belgica.

KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC).

V. Grégoire, J. Machiels, J. Waldron, 2018, Annals of Oncology.

Critical Issues in Head and Neck Oncology: Key Concepts from the Eighth THNO Meeting

V. Budach, J. Machiels, B. O'Sullivan, 2018 .

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS e ESMO e ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up y sore tongue or non-healing

C. R. Leemans, J. Machiels, L. Licitra, 2020 .

PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors.

J. Machiels, D. Cunningham, A. Awada, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.

J. Machiels, L. Buisseret, N. Wald, 2021 .

Carotid stenting for impending carotid blowout: suitable supportive care for head and neck cancer patients?

V. Grégoire, J. Machiels, M. Hamoir, 2005, Palliative medicine.

Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

T. Zander, J. Machiels, J. Schellens, 2016 .

5025 A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy

J. Machiels, M. Campone, X. Pivot, 2009 .

J. Machiels, K. Harrington, M. Ahn, 2018 .

Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment

J. Machiels, B. Filleul, T. Duprez, 2016, Urologia Internationalis.

Osteomalacia due to chemotherapy-induced Fanconi syndrome in an adult patient.

J. Machiels, M. Berlière, J. Devogelaer, 2005, Gynecologic oncology.

Incidence of reversible amenorrhea in women with early-stage breast cancer undergoing adjuvant anthracyclin-based chemotherapy with or without docetaxel.

J. Machiels, M. Berlière, F. Dalenc, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer

M. Groenvold, J. Machiels, S. Tribius, 2020 .

Tubulocystic Carcinoma of the Kidney with Fatal Outcome in an Adolescent Male

J. Machiels, M. Gizzi, S. Aydın, 2014, Urologia Internationalis.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial.

J. Machiels, P. Forget, P. Coulie, 2013, Medical hypotheses.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

J. Machiels, S. Hansen, S. Oudard, 2010, The Lancet.

L. Collette, E. Coche, J. Machiels, 2012, European urology.

J. Machiels, J. Vermorken, E. Ehrnrooth, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Annals of Oncology

J. Machiels, J. Vermorken, K. Pelling, 2022 .

A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell

J. Machiels, K. Sultanem, W. Parulekar, 2018, Annals of Oncology.

An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).

J. Machiels, R. Ferris, S. Topalian, 2017 .

Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)

J. Machiels, C. Sternberg, J. Bellmunt, 2013, Oncology.

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

A. Ravaud, S. Culine, J. Machiels, 2015, European journal of cancer.

Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.

J. Machiels, R. Lhommel, A. Gillain, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).

J. Machiels, S. Schmitz, E. Bompas, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study.

J. Machiels, T. Gauler, A. Dietz, 2013 .

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.

J. Machiels, J. Bogaerts, I. Tinhofer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer

W. A. Noortman, D. Vriens, L. de Geus-Oei, 2023, Cancers.

[Lymph node metastases from squamous cell carcinoma of unknown primary site. Is it time to change of paradigm?].

H. Reychler, V. Grégoire, J. Machiels, 2014, Bulletin du cancer.

Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery.

J. Machiels, P. Forget, M. Berlière, 2014, British journal of anaesthesia.

Reversible myocardial dysfunction in a patient with alcoholic ketoacidosis: a role for hypophosphatemia.

J. Machiels, J. Donckier, A. Dive, 1998, The American journal of emergency medicine.

Stage shift and relative survival for head and neck cancer during the 2020 COVID-19 pandemic: a population-based study of temporal trends

G. Silversmit, J. Machiels, L. van Eycken, 2023, Frontiers in oncology.

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

J. Machiels, S. Srinivas, J. Picus, 2012, Clinical Cancer Research.

Abstract CT118: Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signsof clinical activity in immune-resistant advanced cancers

J. Machiels, S. Rottey, C. Jungels, 2021, Clinical Trials.

Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy

J. Machiels, Q. Le, D. Rischin, 2022, International Journal of Radiation Oncology*Biology*Physics.